Tag Archives: ADA

Fairbanks Presents Research at ADA

Fairbanks Pharmaceuticals CEO Alan Schneyer a American Diabetes AssociationOn Sunday, June 24th, Fairbanks Pharmaceuticals CEO Dr. Alan Schneyer presented a poster at the American Diabetes Association meeting in Orlando entitled “FSTL3 Inhibition Restores Glucose Responsive Insulin Secretion In Non-Functional Human Islets”. 

The  poster describes identification of FSTL3 neutralizing monoclonal antibodies, verification of their specificity and ability to inhibit FSTL3 binding to activin A and B as well as GDF11, and the ability of these antibodies to disrupt pre-formed FSTL3-activin complexes that otherwise are stable. 

Also shown was experiments in which human islets that lost their ability to secrete insulin in response to glucose (the most critical contribution of the beta cells) were restored to glucose responsiveness after exposure to Fairbanks’ antibodies.  These results support further development of this FSTL3 neutralizing approach as a novel therapy for diabetes.